Darlene M Deptula-hicks - Net Worth and Insider Trading
Darlene M Deptula-hicks Net Worth
The estimated net worth of Darlene M Deptula-hicks is at least $51,139 dollars as of 2024-05-17. Darlene M Deptula-hicks is the Executive VP of Finance, CFO of icad Inc and owns about 28,237 shares of icad Inc (ICAD) stock worth over $49,979. Darlene M Deptula-hicks is the SVP, CFO of Pieris Pharmaceuticals Inc and owns about 63 shares of Pieris Pharmaceuticals Inc (PIRS) stock worth over $709. Darlene M Deptula-hicks is also the SVP & CFO of T2 Biosystems Inc and owns about 80 shares of T2 Biosystems Inc (TTOO) stock worth over $451. Details can be seen in Darlene M Deptula-hicks's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Darlene M Deptula-hicks has not made any transactions after 2017-06-06 and currently still holds the listed stock(s).
Transaction Summary of Darlene M Deptula-hicks
Darlene M Deptula-hicks Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Darlene M Deptula-hicks owns 6 companies in total, including Xenetic Biosciences Inc (XBIO) , T2 Biosystems Inc (TTOO) , and Pieris Pharmaceuticals Inc (PIRS) among others .
Click here to see the complete history of Darlene M Deptula-hicks’s form 4 insider trades.
Insider Ownership Summary of Darlene M Deptula-hicks
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| XBIO | Xenetic Biosciences Inc | 2016-11-01 | director |
| TTOO | T2 Biosystems Inc | 2017-06-06 | Chief Financial Officer |
| PIRS | Pieris Pharmaceuticals Inc | 2016-06-13 | Sr. Vice President and CFO |
 | | 2010-03-11 | Executive VP of Finance & CFO |
| | 2006-03-15 | director |
| | 2023-03-08 | See Remarks |
Darlene M Deptula-hicks Latest Holdings Summary
Darlene M Deptula-hicks currently owns a total of 3 stocks. Among these stocks, Darlene M Deptula-hicks owns 28,237 shares of icad Inc (ICAD) as of March 11, 2010, with a value of $49,979 and a weighting of 97.73%. Darlene M Deptula-hicks owns 63 shares of Pieris Pharmaceuticals Inc (PIRS) as of June 13, 2016, with a value of $709 and a weighting of 1.39%. Darlene M Deptula-hicks also owns 80 shares of T2 Biosystems Inc (TTOO) as of June 6, 2017, with a value of $451 and a weighting of 0.88%.
Latest Holdings of Darlene M Deptula-hicks
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ICAD | icad Inc | 2010-03-11 | 28,237 | 1.77 | 49,979 |
| PIRS | Pieris Pharmaceuticals Inc | 2016-06-13 | 63 | 11.25 | 709 |
| TTOO | T2 Biosystems Inc | 2017-06-06 | 80 | 5.64 | 451 |
Holding Weightings of Darlene M Deptula-hicks
Darlene M Deptula-hicks Form 4 Trading Tracker
According to the SEC Form 4 filings, Darlene M Deptula-hicks has made a total of 0 transactions in icad Inc (ICAD) over the past 5 years. The most-recent trade in icad Inc is the sale of 5,000 shares on March 11, 2010, which brought Darlene M Deptula-hicks around $35,000.
According to the SEC Form 4 filings, Darlene M Deptula-hicks has made a total of 0 transactions in Pieris Pharmaceuticals Inc (PIRS) over the past 5 years. The most-recent trade in Pieris Pharmaceuticals Inc is the acquisition of 63 shares on June 13, 2016, which cost Darlene M Deptula-hicks around $8,300.
According to the SEC Form 4 filings, Darlene M Deptula-hicks has made a total of 0 transactions in T2 Biosystems Inc (TTOO) over the past 5 years. The most-recent trade in T2 Biosystems Inc is the acquisition of 80 shares on June 6, 2017, which cost Darlene M Deptula-hicks around $14,320.
Insider Trading History of Darlene M Deptula-hicks
- 1
Darlene M Deptula-hicks Trading Performance
GuruFocus tracks the stock performance after each of Darlene M Deptula-hicks's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Darlene M Deptula-hicks is 10.62%. GuruFocus also compares Darlene M Deptula-hicks's trading performance to market benchmark return within the same time period. The performance of stocks bought by Darlene M Deptula-hicks within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Darlene M Deptula-hicks's insider trading performs compared to the benchmark.
Performance of Darlene M Deptula-hicks
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -5.55 | | | | | |
| Relative Return to S&P 500(%) | -6.91 | | | | | |
Darlene M Deptula-hicks Ownership Network
Darlene M Deptula-hicks Owned Company Details
What does Xenetic Biosciences Inc do?
Who are the key executives at Xenetic Biosciences Inc?
Darlene M Deptula-hicks is the director of Xenetic Biosciences Inc. Other key executives at Xenetic Biosciences Inc include Chief Financial Officer James F Parslow , Chief Scientific Officer Curtis Lockshin , and 10 percent owner Pharmsynthez Pjsc .
Xenetic Biosciences Inc (XBIO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Xenetic Biosciences Inc (XBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Xenetic Biosciences Inc (XBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Xenetic Biosciences Inc (XBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xenetic Biosciences Inc Insider Transactions
Darlene M Deptula-hicks Mailing Address
Above is the net worth, insider trading, and ownership report for Darlene M Deptula-hicks. You might contact Darlene M Deptula-hicks via mailing address: C/o Icad, Inc., 98 Spit Brook Road, Suite 100, Nashua Nh 03062.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
